Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020

Lisa Nodzon

首页> 外文期刊>Journal of the advanced practitioner in oncology >Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020

【24h】

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020

机译：慢性淋巴细胞白血病中的最小残留疾病：Soho 2020的亮点

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL) is evolving as an important concept in patient treatment algorithms due to the availability of drug combinations capable of inducing complete responses (CR). Such achievement raises the concept of time-limited therapy in an incurable disease outside of bone marrow transplant. While ibrutinib (Imbruvica), a Bruton tyrosine kinase inhibitor (BTKi), has improved progression-free survival (PFS) and overall survival (OS), including in patients with poor prognostic features, CRs are rare, with deeper responses improving over time. Therefore, ibrutinib is maintained until disease progression or intolerance.

机译：由于能够诱导完全应答（CR）的药物组合的可用性，慢性淋巴细胞白血病（CLL）的微小残留病（MRD）检测正在成为患者治疗算法中的一个重要概念。这一成就提出了在骨髓移植之外对一种不治之症进行限时治疗的概念。虽然布鲁顿酪氨酸激酶抑制剂（BTKi）伊布替尼（Imbruvica）改善了无进展生存率（PFS）和总生存率（OS），包括预后不良的患者，但CRs很少见，随着时间的推移，更深层次的反应会改善。因此，伊布替尼一直维持到疾病进展或不耐受。

著录项

来源
《Journal of the advanced practitioner in oncology》 |2021年第1期|共3页
作者
Lisa Nodzon;
展开▼
作者单位

Moffitt Cancer Center;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation [J] . Yifei Cheng, Kaiyan Liu, Shasha Wang, 工程（英文） . 2019,第001期
2. Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation [J] . Yifei Cheng, Yuhong Chen, Chenhua Yan, 工程（英文） . 2019,第001期
3. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma [J] . Travers Ching, Megan E. Duncan, Tera Newman-Eerkes, BMC Cancer . 2020,第1期

机译：用于在急性淋巴细胞白血病，慢性淋巴细胞白血病和多发性骨髓瘤中建立可测量（最小）残留疾病的Clonoseq测定的分析评估
4. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. [J] . Montillo M, Schinkoethe T, Elter T Cancer investigation . 2005,第6期

机译：B细胞慢性淋巴细胞性白血病（B-CLL）患者用Alemtuzumab消除的最小残留疾病：需要一种标准的检测方法以及骨髓清除对疾病预后的潜在影响。
5. Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial [J] . Olivier Tournilhac, Magali Le Garff-Tavernier, Stéphanie Nguyen Quoc, Haematologica . 2021,第7期

机译：单体性造血干细胞移植治疗高危慢性淋巴细胞白血病的最小残留疾病驱动免疫干预的疗效：前瞻性多中心试验的结果
6. Global Sensitivity Analysis for a Model of B-Cell Chronic Lymphocytic Leukemia Disease Trajectories [C] . Symeon Savvopoulos, Ruth Misener, Nicki Panoskaltsis European Symposium on Computer Aided Process Engineering . 2015

机译：B细胞慢性淋巴细胞白血病术术模型的全局敏感性分析
7. Risk Factors for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Incidence in Postmenopausal Women: A Women's Health Initiative (WHI) Study [D] . Maharry, Kati S. 2016

机译：绝经后妇女慢性淋巴细胞白血病和小淋巴细胞淋巴瘤发生率的危险因素：妇女健康倡议（WHI）研究
8. Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020 [O] . 2021

机译：慢性淋巴细胞白血病中的最小残留疾病：SOHO 2020的亮点
9. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma [O] . Travers Ching, Megan E. Duncan, Tera Newman-Eerkes, 2020

机译：用于在急性淋巴细胞白血病，慢性淋巴细胞白血病和多发性骨髓瘤中建立可测量（最小）残留疾病的Clonoseq测定的分析评估
10. Quantitative Risk Assessment of Exposures to Butadiene in European Union Occupational Settings based on the University of Alabama at Birmingham Epidemiological Study: Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myelogenous Leukemia [R] . Sielken, R. L., Valdez-Flores, C., Delzell, E. 2007

机译：基于阿拉巴马大学伯明翰分校的流行病学研究：欧洲职业环境中丁二烯暴露的定量风险评估：急性髓性白血病，慢性淋巴细胞白血病和慢性粒细胞白血病

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020

摘要

著录项

相似文献

相关主题

期刊订阅